Orion Infusion to invest Tk20cr to expand IV fluids production

Orion Infusion Limited has announced a Tk20.50 crore investment — including working capital — to expand its intravenous (IV) fluids production line amid growing domestic demand.

In a disclosure today (10 November), the company said its board of directors has approved the investment, which will be fully financed from internal sources. Construction at its Maikuli plant in Rupganj, Narayanganj, will begin soon, with completion targeted for December 2026.

Once operational, the new facility is expected to increase the company's production capacity by around 30%, enabling it to better meet the rising market demand for IV fluids. 

The expansion is projected to generate additional annual sales of Tk25.50 crore, which the company says will significantly strengthen profitability.

Following the announcement, Orion Infusion's share price surged by 3.71% to close at Tk388.80 on the Dhaka Stock Exchange today, reflecting strong investor confidence in the company's growth plan.

Meanwhile, the board of directors has also declared a 20% cash dividend for general shareholders for the fiscal year 2024-25, according to a company disclosure.

For FY25, the company reported earnings per share (EPS) of Tk1.72, while its net asset value per share (NAVPS) stood at Tk16.02 as of 30 June 2025.

The company's annual general meeting (AGM) will be held on 23 December 2025, during which shareholders will approve the dividend and other agenda items. The record date for determining eligible shareholders has been fixed for 1 December 2025.

Orion Infusion, a concern of the Orion Group, is one of the country's leading manufacturers of IV saline and life-saving infusion products, supplying hospitals and clinics across Bangladesh.